Biomarin Pharmaceutical vs Biontech
Biomarin Pharmaceutical and Biontech are similar in size: $3.22bn and $3.24bn of revenue in their latest fiscal years. Biomarin Pharmaceutical grew faster (12.9% against 9.0%). Biomarin Pharmaceutical kept more of each dollar of sales as profit: a net margin of 10.8% against -39.6%. Biontech carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | Biomarin PharmaceuticalBMRN, 2025 | BiontechBNTX, 2025 |
|---|---|---|
| Revenue | $3.22bn | $3.24bn |
| Revenue growth | 12.9% | 9.0% |
| Net income | $349m | −$1.28bn |
| Operating margin | 12.7% | -49.0% |
| Net margin | 10.8% | -39.6% |
| Return on equity | 5.9% | -6.0% |
| Free cash flow | $725m | $318m |
| Cash | $1.31bn | $9.01bn |
| Total debt | $600m | $0 |
| Debt to equity | 9.9% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | 0.0% |
| Share buybacks | — | — |
| Employees | 3,221 | — |
| Market value | $10.80bn | $21.84bn |
| Price vs our value range | Within our value range | Below our value range |
| Moat score | 40 (Weak) | — |
| Insider trades, 12 months | 0 buys, 5 sales | 0 buys, 27 sales |